Urothelial Cancer

The resubmission of an sBLA of nogapendekin alfa inbakicept plus BCG in BCG-unresponsive, papillary-only NMIBC was discussed with the FDA.

Andrea Necchi, MD, PhD, discusses data from GDFather-NEO evaluating nivolumab plus visugromab in cisplatin-ineligible MIBC.

The FDA approval of perioperative enfortumab vedotin plus pembrolizumab reshapes curative-intent care for cisplatin-ineligible MIBC.

Christof Vulsteke, MD, PhD, discusses the clinical rationale for evaluating perioperative enfortumab vedotinplus pembrolizumab in patients with cisplatin-ineligible MIBC.

Anamorelin plus chemotherapy was well tolerated and potentially associated with efficacy in metastatic urothelial carcinoma.

Treatment with nogapendekin alfa inbakicept plus BCG prolonged duration of complete response compared with BCG alone in patients with BCG-naive NMIBC.

Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

Christof Vulsteke, MD, PhD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible MIBC.

Dr Vulsteke discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer.

Primo Nery “Lucky” Lara Jr, MD, has built a genitourinary oncology career inspired by optimism, rooted in perseverance, expanded by innovative thinking, and strengthened by a belief in the power of team science.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

Enfortumab vedotin plus pembrolizumab is the first perioperative regimen without chemotherapy to improve both EFS and OS in cisplatin-eligible MIBC.

The EMA recommended conditional marketing authorization for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS.

Lorraine Scanlon, MD, discusses IVC tumor thrombus in RCC, its management, and how relieving venous congestion may improve renal function and guide future care.

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.

Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.